Sparsentan:a non-immunosuppressive drug treating IgA nephropathy
JI Ya-chun
JIA Hui-xia
QI Jun-sheng
Abstract：On February 17,2023,sparsentan received accelerated approval from the FDA in the USA for reduction of proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression,generally a urine protein-to-creatinine ratio(UPCR)≥1.5 g·g-1.This makes it the only approved non-immunosuppressive drug for the treatment of immunoglobulin A kidney disease(IgAN).Sparsentan is a novel non-immunosuppressive,monomolecular,dual endothelin-angiotensin receptor antagonist,which can double block endothelin type A(ETA)and angiotensin type Ⅱ type 1 receptor(AT1),and play a role in protecting glomerular podocytes and reducing proteinuria.Although the US FDA drug label contains two black box warnings against sparsentan,clinical trials have shown that sparsentan is well tolerated with a consistent and manageable safety profile.Furthermore,sparsentan provides significant clinical benefit compared to irbesartan treatment,resulting in a significant reduction in proteinuria and preservation of kidney function.
Keywords：immunoglobulin A kidney diseaseproteinuriasparsentankidney functionnon-immuno-suppressive
Publication Date：2025-02-14
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 225-230 )